Current Report Filing (8-k)
May 17 2021 - 9:56AM
Edgar (US Regulatory)
0001580149
false
0001580149
2021-05-17
2021-05-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 17, 2021
BioVie Inc.
|
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
001-39015
|
|
46-2510769
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
2120 Colorado Avenue, Suite 230
Santa Monica, California
|
|
90404
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(310)
444-4300
(Registrants Telephone Number, Including Area Code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
o
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class:
|
|
Trading
Symbol(s):
|
|
Name
of Each Exchange on Which Registered:
|
Class A Common Stock, par value
$0.0001 per share
|
|
BIVI
|
|
The
NASDAQ Stock Market, LLC
|
|
|
|
|
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item
7.01 Regulation FD Disclosure.
Beginning on May 17, 2021, BioVie Inc. (the Company)
plans to make a series of investor presentations (the Corporate Presentation
and the R&D Day Presentation) copies of which is attached as Exhibit 99.1 and 99.2, respectively;
to this Current Report on Form 8-K and is incorporated herein by reference. The Company also expects to use the Investor
Presentation at the BRiley Conference beginning on May 19, 2021 and from time to time thereafter in connection with presentations
to potential investors, industry analysts and others. The Investor Presentation is available under the Events and Presentations
tab in the Investors section of the Companys website, located at www.biovie.com.
By
filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to
the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.
The information contained in the Corporate
Presentation and the R&D Day Presentation is summary information that is intended to be considered in the context of
the Companys Securities and Exchange Commission (SEC) filings and other public announcements that the Company
may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or
revise the information contained in this report, although it may do so from time to time as its management believes is warranted.
Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through
other public disclosure.
The information presented in Item 7.01 of this Current Report
on Form 8-K and Exhibit 99.1 and 99.2 shall not be deemed to be filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of
that section, unless the Company specifically states that the information is to be considered filed under the Exchange
Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
|
*
|
Schedules
and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish the omitted schedules and exhibits
to the Securities and Exchange Commission upon request.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
May 17, 2021
|
BIOVIE
INC.
|
|
|
|
|
|
|
By:
|
/s/
Joanne Wendy Kim
|
|
|
Name:
|
Joanne
Wendy Kim
|
|
|
Title:
|
Chief
Financial Officer
|
|
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Apr 2023 to Apr 2024